← Back to Clinical Trials
Recruiting NCT07019857

NCT07019857 Impact of Thymectomy on Immunity in Infants After Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07019857
Status Recruiting
Phase
Sponsor Nantes University Hospital
Condition Congenital Heart Defects
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2025-07-25
Primary Completion 2027-12-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 6 Months
Study Type INTERVENTIONAL
Interventions
Blood sample collection at surgery time and 12 months later

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2025-07-25 with a primary completion date of 2027-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Heart surgery in infants typically involves complete removal of the thymus gland to improve access to the heart. However, the thymus plays a key role in developing the immune system in early childhood, especially in the production and maturation of T lymphocytes, which help the body defend itself against infections. The THYMIC study tests the hypothesis that partial removal of the thymus (partial thymectomy) during heart surgery may better preserve the child's immune function compared to total removal (complete thymectomy). The goal is to determine whether this conservative surgical approach could reduce the risk of immune system impairment and infections in the months following surgery. This is a prospective, interventional, single-center study conducted at CHU de Nantes, involving 3 groups of infants: * One group undergoing heart surgery with complete thymectomy; * One group undergoing heart surgery with partial thymectomy; * One control group undergoing heart or non-heart surgery without thymus removal. All infants enrolled will have two blood tests: one taken during their surgery and one taken one year later. These blood tests will quantify immune cells (T, B, NK cells), levels of antibodies, and vaccine responses. Parents will also be asked to fill out a questionnaire to record any infections their child experiences during the year after surgery. By comparing the immune responses and infection rates among the groups, the researchers hope to better understand the long-term effects of thymectomy in infants. The results could support future recommendations to preserve part of the thymus when possible during heart surgery. Participation in the study does not change the medical or surgical care of the child. The decision to perform a partial or complete thymectomy is made by the surgeon based on the child's anatomy. The additional blood samples are small in volume and follow current safety regulations.

Eligibility Criteria

Inclusion Criteria: * \- Children aged between 0 and 6 months; * Born at a gestational age \> 37 weeks' gestation; * With an indication for cardiac surgery under CEC at Nantes University Hospital; * Cardiopediatric follow-up planned at Nantes University Hospital; * Written agreement signed by legal guardians to participate in the study. For the control groups: * Control group A (cardiac surgery without thymectomy): * Children aged between 0 and 6 months of age; * Born at a gestational age \> 37 SA; * Indicated for thoracotomy cardiac surgery at Nantes University Hospital; * Cardiopediatric follow-up planned at Nantes University Hospital; * Written agreement signed by legal guardians to participate in the study. * Control group B (non-cardiac surgery) * Children aged between 0 and 6 months; * Born at a gestational age \> 37 SA; * Indicated for non-cardiac surgery (ENT or visceral surgery at Nantes University Hospital); * Planned follow-up surgery at Nantes University Hospital; * Written agreement signed by legal guardians to participate in the study. Exclusion Criteria : * Gestational age \< 37 SA; * With a history of cardiac surgery under ECG; * And/or with heart disease requiring further surgery within 12 months of the 1st surgery (e.g. pulmonary cerclage, systemic pulmonary anastomosis). * And/or a history of partial or complete thymectomy; * Receiving long-term immunosuppressive treatment; * Post-operative follow-up planned in a hospital other than Nantes University Hospital, or moving house planned during the follow-up period; * parental refusal. Exclusion Criteria: * \- Gestational age \< 37 SA; * With a history of cardiac surgery under ECG; * And/or with heart disease requiring further surgery within 12 months of the 1st surgery (e.g. pulmonary cerclage, systemic pulmonary anastomosis). * And/or a history of partial or complete thymectomy; * Receiving long-term immunosuppressive treatment; * Post-operative follow-up planned in a hospital other than Nantes University Hospital, or moving house planned during the follow-up period; * parental refusal.

Contact & Investigator

Central Contact

Alexis Chenouard, PH

✉ alexis.chenouard@chu-nantes.fr

📞 02 44 76 82 21

Principal Investigator

Alexis Chenouard, PH

PRINCIPAL INVESTIGATOR

Nantes University Hospital

Frequently Asked Questions

Who can join the NCT07019857 clinical trial?

This trial is open to participants of all sexes, up to 6 Months, studying Congenital Heart Defects. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07019857 currently recruiting?

Yes, NCT07019857 is actively recruiting participants. Contact the research team at alexis.chenouard@chu-nantes.fr for enrollment information.

Where is the NCT07019857 trial being conducted?

This trial is being conducted at Nantes, France, Nantes, France.

Who is sponsoring the NCT07019857 clinical trial?

NCT07019857 is sponsored by Nantes University Hospital. The principal investigator is Alexis Chenouard, PH at Nantes University Hospital. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology